On October 3, 2014, ProQR Therapeutics N.V. announced the appointment of Smital Shah as its new Chief Financial Officer, effective immediately. Ms. Shah has a track record of management and leadership experience in the biopharmaceutical industry as well as in investment banking, with a particular focus on financial strategy and capital markets. Ms. Shah joins the company from Gilead Sciences Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 USD | -1.03% | -3.03% | -3.03% |
May. 09 | Transcript : ProQR Therapeutics N.V. - Special Call | |
May. 09 | ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.03% | 158M | |
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- PRQR Stock
- News ProQR Therapeutics N.V.
- ProQR Therapeutics N.V. Appoints Smital Shah as Chief Financial Officer